Your browser doesn't support javascript.
loading
Cellular Therapies in Chronic Lymphocytic Leukemia and Richter's Transformation: Recent Developments in Chimeric Antigen Receptor T-Cells, Natural Killer Cells, and Allogeneic Stem Cell Transplant.
Coombs, Catherine C; Easaw, Saumya; Grover, Natalie S; O'Brien, Susan M.
Afiliación
  • Coombs CC; Division of Hematology and Oncology, Department of Medicine, University of California Irvine, Orange, CA 92868, USA.
  • Easaw S; Atrium Health, Carolinas Hospitalist Group, Charlotte, NC 28203, USA.
  • Grover NS; Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • O'Brien SM; Division of Hematology and Oncology, Department of Medicine, University of California Irvine, Orange, CA 92868, USA.
Cancers (Basel) ; 15(6)2023 Mar 18.
Article en En | MEDLINE | ID: mdl-36980726
ABSTRACT
Cellular therapies can be viewed as both the newest and oldest techniques for treating chronic lymphocytic leukemia (CLL) and Richter's transformation (RT). On one hand, allogeneic hematopoietic stem cell transplantation (alloHSCT) has been available for decades, though its use is diminishing with the increasing availability of effective novel targeted agents, especially in CLL. Among newer techniques, chimeric antigen receptor T-cells (CAR-T) have demonstrated astounding efficacy in several hematologic malignancies, leading to FDA approval and use in clinical practice. However, though CLL is the earliest disease type for which CAR-T were studied, development has been slower and has yet to lead to regulatory approval. Owing partially to its rarity but also due to the aggressive behavior of RT, CAR-T in RT have only been minimally explored. Here, we will focus on the applications of cellular therapies in CLL and RT, specifically reviewing more recent data related to alloHSCT in the novel-agent era and CAR-T cell development in CLL/RT, focusing on safety and efficacy successes and limitations. We will review strategies to improve upon CAR-T efficacy and discuss ongoing trials utilizing CAR-T in CLL/RT, as well as emerging technologies, such as allogeneic CAR-T and natural killer CAR (CAR NK) cells.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos